Vividion Therapeutics is a biotechnology company that uses integrated discovery technologies to enable precision small‑molecule therapeutics for oncology and immunology. Its platform finds cryptic functional pockets, uses a proteome‑trained covalent chemistry library, and applies industrial‑scale chemoproteomics to ensure selectivity. Leveraging these capabilities, Vividion is advancing a broad pipeline of potent, selective small molecules across oncology and immune indications. The company’s initial wholly owned programs target the KEAP1‑NRF2 axis (both antagonists for NRF2 mutant/addicted cancers and agonists for inflammatory diseases) and, in partnership with Bristol Myers Squibb, a program against a challenging transcription factor. Vividion says it intends to begin advancing programs into the clinic next year. The company is headquartered in San Diego. Vividion Therapeutics is a San Diego-based biotechnology company with a platform to discover small molecule therapeutics against biologically compelling but previously intractable targets. Its platform, built on seminal work from labs at The Scripps Research Institute, enables screening of small molecules against every protein in native biological systems and identifies highly selective binders agnostic to protein class and function. Those binders can be developed into drugs using approaches including direct and allosteric modulation of protein function and targeted protein degradation. The company’s immediate focus is in oncology and immunology. Led by CEO Dr. Diego Miralles, Vividion intends to use new funding to expand operations and advance its research efforts. Vividion Therapeutics has developed a chemical proteomics platform that creates proteome-wide drug interaction maps to identify ligands and targets in native biological systems. The platform is designed to expand the druggable proteome and address targets previously considered undruggable by assessing target engagement and global selectivity early. Vividion applies novel chemistry to accelerate optimization of fragment hits into drug candidates and holds a robust intellectual property estate covering newly recognized druggable sites. The company was spun out of labs at The Scripps Research Institute and was founded with seed financing from Cardinal Partners. Headquartered in San Diego, Vividion focuses on developing transformative therapeutics to treat major unmet clinical needs. In conjunction with its launch financing, the company added experienced industry leadership to its board to support accelerated drug discovery and development.

Total raised

$267M

Funding rounds

3

Latest round

Series C

Latest activity

Feb 2021